K-679
/ Kowa
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 23, 2025
Hepatocyte ApoJ accelerates injury-induced liver fibrosis by activation STAT3 through Ranbp2 mediated-SUMOylation.
(PubMed, Cell Mol Gastroenterol Hepatol)
- "ApoJ plays a pivotal role in accelerating the progression of liver fibrosis. Therapeutic strategies targeting the ApoJ/STAT3/RanBP2 axis may offer a novel approach for the prevention and treatment of fibrotic liver diseases."
Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • CLU • RANBP2 • STAT3 • TGFB1
March 26, 2025
K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs
(AACR 2025)
- "Using this platform, we developed K-679, which combines cetuximab with DM1-loaded unimicelles. Antigen-binding specificity and cellular internalization of K-679 were evaluated using surface plasmon resonance, flow cytometry, and fluorescence microscopy. Our findings establish K-679 as a promising therapeutic candidate for heterogeneous EGFR-expressing solid tumors, characterized by a more potent anti-tumor effect through an exceptionally high DAR, enhanced drug accumulation into tumors and significant bystander effect."
Oncology • Solid Tumor • EGFR
April 21, 2025
K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors
(PRNewswire)
- "Kowa Company...today announced an upcoming presentation of non-clinical data for K-679...The compound, developed using Kowa's proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois."
Preclinical • Solid Tumor
1 to 3
Of
3
Go to page
1